| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/16/2009 | WO2009046865A2 Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent |
| 04/16/2009 | WO2009046864A2 Use of the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046863A2 Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046862A1 Use of physalemin as a therapeutic agent |
| 04/16/2009 | WO2009046861A1 Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent |
| 04/16/2009 | WO2009046860A2 Use of dago as a therapeutic agent |
| 04/16/2009 | WO2009046859A2 Use of af12198 and dago as therapeutic agents |
| 04/16/2009 | WO2009046858A2 Therapeutic uses of kisspeptin 13 and compositions thereof |
| 04/16/2009 | WO2009046857A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046856A2 Use of serorphin as a therapeutic agent |
| 04/16/2009 | WO2009046853A1 Use of intermedin 47 peptide as a therapeutic agent |
| 04/16/2009 | WO2009046852A1 Therapeutic uses of intermedin 47 and 53 peptides |
| 04/16/2009 | WO2009046851A1 Cgrp as a therapeutic agent |
| 04/16/2009 | WO2009046850A1 Cgrp as a therapeutic agent |
| 04/16/2009 | WO2009046849A1 Use of the peptide cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046848A1 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046847A2 Use of peptide ll-37 as a therapeutic agent |
| 04/16/2009 | WO2009046846A2 Use of il-1 receptor peptide, alone or in combination with peptide ll-37, as a therapeutic agent |
| 04/16/2009 | WO2009046845A2 Use of a lactoferrin partial peptide peptide as a therapeutic agent |
| 04/16/2009 | WO2009046844A1 Therapeutic uses of peptide tdvngdgrhdl |
| 04/16/2009 | WO2009046843A1 Therapeutic uses of peptides kvlpvpq and/or tdvngdgrhdl |
| 04/16/2009 | WO2009046835A1 Use of goserelin and amylin as therapeutic agents |
| 04/16/2009 | WO2009046834A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/16/2009 | WO2009046833A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046832A2 Short peptides used in medicine |
| 04/16/2009 | WO2009046831A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046830A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046829A2 Casoxin d as a therapeutic agent |
| 04/16/2009 | WO2009046827A2 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents |
| 04/16/2009 | WO2009046825A1 Use of a peptide acetyl-calpastatin as a therapeutic agent |
| 04/16/2009 | WO2009046824A2 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis |
| 04/16/2009 | WO2009046822A2 Use of the peptide ymdgtmsqv as a therapeutic agent |
| 04/16/2009 | WO2009022066A3 Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 04/16/2009 | WO2009022065A3 Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 04/16/2009 | WO2009022064A3 Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 04/16/2009 | WO2009022063A3 Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 04/16/2009 | WO2009021926A3 Use of a neurotoxin |
| 04/16/2009 | WO2008130630A4 Polymorphic form of rimonabant hydrochloride and processes for preparation thereof |
| 04/16/2009 | WO2008101187A3 Pro-drugs of peripheral phenolic opioid antagonists |
| 04/16/2009 | WO2008047952A3 Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound |
| 04/16/2009 | WO2008011483A3 Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds |
| 04/16/2009 | WO2007008576A3 Oxcarbazepine formulation |
| 04/16/2009 | WO2007005935A3 Norepinephrine transporter radiotracers and methods of syntheses thereof |
| 04/16/2009 | WO2005042727A3 Methods of organ regeneration |
| 04/16/2009 | US20090099264 Fluoroalkylamine Derivatives as Cathepsin Inhibtors |
| 04/16/2009 | US20090099261 Omega-3 mixtures |
| 04/16/2009 | US20090099259 Method for regulating gene expression |
| 04/16/2009 | US20090099251 Dietary and pharmaceutical compositions containing tricyclic diterpenes and their derivatives and their uses |
| 04/16/2009 | US20090099248 Inhibitors of d-amino acid oxidase |
| 04/16/2009 | US20090099242 Heterocyclic inhibitors of necroptosis |
| 04/16/2009 | US20090099241 Pharmaceutical composition containing antihypertensive agents |
| 04/16/2009 | US20090099236 treatment of depression, anxiety, genitourinary diaorders, pain; monoamine reuptake inhibitors, triple and/or dual reuptake inhibitors of norepinephrine, serotonin, and dopamine; methyl-[3-(3-methyl-1H-indazol-5-yl)-3-phenyl- propyl]-amine |
| 04/16/2009 | US20090099233 Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| 04/16/2009 | US20090099232 Injectable depot formulation comprising crystals of iloperidone |
| 04/16/2009 | US20090099230 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 04/16/2009 | US20090099228 insomnia or eating disorders such as anorexia; 2-{1-Ethyl-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-3-methyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-N-methyl-2-phenyl-acetamide for example |
| 04/16/2009 | US20090099217 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies |
| 04/16/2009 | US20090099215 Metabolic enhancing properties of norphenephrine and its salts |
| 04/16/2009 | US20090099208 Novel guanidine derivatives and their medical use |
| 04/16/2009 | US20090099207 Cyclic sulfones useful as BACE inhibitors |
| 04/16/2009 | US20090099179 Compounds for diseases and disorders |
| 04/16/2009 | US20090099178 Indazole compounds and methods of use thereof |
| 04/16/2009 | US20090099175 Phosphodiesterase 10 inhibitors |
| 04/16/2009 | US20090099172 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES |
| 04/16/2009 | US20090099164 Phenylaminopropanol Derivatives and Methods of Their Use |
| 04/16/2009 | US20090099159 Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds |
| 04/16/2009 | US20090099158 Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
| 04/16/2009 | US20090099155 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| 04/16/2009 | US20090099139 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 04/16/2009 | US20090099137 Anti-Inflammatory Compounds and Uses Thereof |
| 04/16/2009 | US20090099110 Antiviral oligonucleotides |
| 04/16/2009 | US20090099100 Compositions and methods for treating amyloidosis |
| 04/16/2009 | US20090099069 Modulators of alpha-synuclein toxicity |
| 04/16/2009 | US20090098221 Creatine ascorbyl derivatives and methods of use thereof |
| 04/16/2009 | US20090098202 Extended Release Formulation |
| 04/16/2009 | US20090098114 ALK7 and myostatin inhibitors and uses thereof |
| 04/16/2009 | US20090098109 Compositions and Methods For Enhancing Neuronal Plasticity and Regeneration |
| 04/16/2009 | US20090098105 Treatment of neurodegenerative diseases by the use of scd4 inhibitors |
| 04/16/2009 | US20090098096 Agent for correcting stress-inducing neuro-mediator, neuro-endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions |
| 04/16/2009 | CA2702171A1 Amide compound |
| 04/16/2009 | CA2702008A1 Inhibitors of protein kinases |
| 04/16/2009 | CA2701853A1 Organic compounds |
| 04/16/2009 | CA2701788A1 Humanized antibody |
| 04/16/2009 | CA2701189A1 Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| 04/16/2009 | CA2700803A1 Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes |
| 04/16/2009 | CA2699674A1 5-ht7 receptor antagonists |
| 04/16/2009 | CA2699504A1 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders |
| 04/16/2009 | CA2699257A1 Cgrp as a therapeutic agent |
| 04/16/2009 | CA2699169A1 Therapeutic uses of intermedin 47 and 53 peptides |
| 04/16/2009 | CA2699168A1 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 04/16/2009 | CA2699163A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2699088A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2699084A1 Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent |
| 04/16/2009 | CA2699083A1 Use of a peptide as a therapeutic agent |
| 04/15/2009 | EP2048229A1 Human artificial chromosome (hac) vector, and human cell pharmaceutical comprising human artificial chromosome (hac) vector |
| 04/15/2009 | EP2048162A1 Novel monoclonal antibody and use of the same |
| 04/15/2009 | EP2048150A1 Benzyl phenyl glucopyranoside derivative |
| 04/15/2009 | EP2048143A1 Prodrug of cinnamide compound |
| 04/15/2009 | EP2048138A1 Salt or solvate of 5-methyl-2-(piperazin-1-yl)benzenesulfonic acid |
| 04/15/2009 | EP2048135A1 Use of monohydroxycarbamazepine in the treatment of neuropathic pain and related disorders |